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IL-1 is one of the major mediators of immunity and inflammation in mammals .
Secreted by mononuclear phagocytes (monocytes, macrophages, and other related
cells of this lineage) in response to many inert, immunologic, or microbial agents,
IL-1 induces maturation anddifferentiation in T lymphocytes, induces acute phase
serumreactant production by the liver, induces feverviathehypothalamus, increases
prostaglandin and collagenase production by cultured synovial cells, and induces
fibroblast proliferation andprostaglandin production in vitro (reviewed in reference 1) .
The ubiquity and potency of IL-1 in these and other physiologic systems suggest
that its effects must be tightly regulated . Accordingly, a number of substances capable
of inhibiting the effects of IL-1 have been reported, including molecules that have
been derived from human urine (2-5), from normal human white blood cells (6,
7), from human white blood cells in certain disease states (8, 9) or after viral infec-
tion (10, 11), fromhumanepidermal cells (12), and from avariety ofcell lines (13-16) .
We have previously reported that theurine of febrile humans contains largeamounts
ofa 30-40-kD glycoprotein inhibitor of IL-1-induced mouse thymocyte prolifera-
tion (3, 17) . Based upon differences in size and functional activity, this factor seems
to be distinct from two other urine-derived IL-1 inhibitors, uromodulin (18-20), and
an inhibitor first derived from the urine of patients with monocytic leukemia (5,
21). However, the febrile inhibitor has not been purified, thereby hindering more
exact biological and physiochemical characterization . We have, therefore, under-
taken to purify this molecule usingmethodology that produced reasonable amounts
of biologically active material . In this report we describe the successful purification
of this factor to homogeneity . It appears to be a glycoprotein of 38 kD in size, with
amino acid sequence homology and bioactivity similar to DNase I.
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Patient Population .
Materials and Methods
Urine was collected from febrile patients, or patients under treatment or recovering from
recent febrile illnesses. The majority were patients with acute or chronic tuberculosis on an-
timycobacterial therapy . Most were also males because of the relative ease of collection of
uncontaminated urine . Patients with documented or suspected HIV infection were excluded,
as were all individuals from HIV infection high risk groups (male homosexuals and intrave-
nous drug abusers) .
Urine Collection .
All urine voided during a 24-h period was collected into 2-liter plastic containers containing
sufficient granular ammonium sulfate, and sodium azide, so that the concentration of satu-
rated ammonium sulfate would be 40%, and sodium azide would be 0.04% when the con-
tainers contained 1 liter of fluid . Urines were allowed to stand at room temperature, and
were collected daily . Once collected, the urine volumes or amounts of salt were adjusted so
that each specimen contained exactly 40% ammonium sulfate, and 0.04% sodium azide .
These were pooled and stored at 4°C until processed further. All further procedures were
performed at 4°C .
Urine Filtration and Concentration .
Pooled urines were processed in large batches (20-80 liters) . Ammonium sulfate-insoluble
urine precipitate was first allowed to settle by gravity sedimentation . Supernatant material
was filtered through a 1.1-um Acrodisc cartridge filter (Gelman Scientific, Northbrook, IL) .
The filtered urine was then concentrated in a Hollow Fiber Concentrator with a 10,000 mol
wt cut-off (HP10; Amicon Corp ., Danvers, MA). It was concentrated to a final volume of
-1,000 ml, and then diafiltered against double glass-distilled water until the ammonium sulfate
concentration was <1% .
Inhibitor Purification.
All subsequent procedures were performed at 4°C, and all buffers and dialysis fluids con-
tained PEG-1,000 (0.01 g/liter) (Sigma Chemical Co., St . Louis, MO) . All buffers and dial-
ysis fluids were made with double glass-distilled water. From theACA-54 fractionation pro-
cedure onward, the preparation was treated at the beginningofeach step with 1mM(PMSF)
(Sigma Chemical Co.) to inhibit endogenous protease activity. Preparations were clarified
and sterilized by passage through a 0.22-wm filter (Millex-GM ; Millipore Continental Water
Systems, Bedford, MA) before each column chromatographic step .
Salting Out with Ammonium Sulfate .
￿
The diafiltered urine was first subjected to salting out
with 80% saturated ammonium sulfate . After the addition of the appropriate amount of
granularammonium sulfate, the urine was allowed to stand at 4°C overnight with slow mixing .
The insoluble material was collected by centrifugation at 10,000 RPM for 30min in a high-
speed centrifuge (RC2B ; Sorvall, Newtown, CT) . The protein pellet was resuspended in a
minimum volume of distilled water (usually 400-800 ml), and dialyzed against 4 liters of
distilled water, with four changes over a 48-h period . At the end of this time, the material
was clarified by centrifugation (10,000 RPM x 30 min), and the resolubilized proteins in
the supernatant were saved.
Ion Exchange Chromatography.
￿
The pooled preparation of urine proteins that were soluble
in 40% ammonium sulfate and insoluble at 80% ammonium sulfate were next subjected
to fractionation by ion exchange chromatography. Pooled material was buffered with 10mM
sodium phosphate buffer, pH 7.5 . This material was applied to a Tris-AcrylDEAF gel (Phar-
macia Fine Chemicals, Piscataway, NJ) in a 2.5 x 25 cm column at a flow rate of 40 ml/h .
After application ofthe sample, the column was washed with 10mM phosphate buffer until
the amount of protein eluting from the column, as measured by the absorption at 280 nm
(Azso), returned to the baseline level . Proteins were eluted from the column using a step-
wise gradient of sodium chloride in 10 mM phosphate buffer, pH 7.5 (50mM NaCl, 250
mM NaCl, and 1 M NaCl) . At each step the column was rinsed until the Also returned to
baseline . The urine preparation that remained bound after the 50-mM salt wash, but wasROSENSTREICH ET AL.
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eluted by the 250-mM salt wash, was pooled and saved for further purification. This material
had previously been found to contain the majority of the urine IL-1 inhibitor activity (17).
Molecular Sieve Chromatography. The 50-250 mM salt eluate preparation was next subjected
to molecular sieve chromatography on an ACA-54 gel (Pharmacia Fine Chemicals). The prep-
aration was first concentrated to a volume of 5-6 ml using a flat membrane filter with a
10,000-mol wt cut-off, in a 50-ml stirred cell (YM-10 membrane, Amicon Corp.). This mate-
rial was diafiltered with PBS (100 mM NaCl, 50 mM sodium phosphate buffer, pH 7.4).
The concentrated material was applied to the top of a 2.5 x 84-cm glass column containing
the ACA-54 gel, at a flow rate of 28 ml/h, and the proteins were eluted from the column
using PBS. The column was precalibrated using 1 mg/ml protein standards (BSA; mol wt,
67,000; OVA, mol wt, 45,000; chymotrypsinogen; mol wt, 25,000; and cytochrome C; mol
wt, 12,500). The proteins that eluted from the column with apparent mol wt between 25,000
and 45,000 were pooled and subjected to further purification.
Hydrophobic Chromatography.
￿
The pooled material from the ACA-54 column was concen-
trated using a YM-10 filter and brought to a volume of 20-30 ml. This was then diafiltered
into 10 mM potassium phosphate buffer, pH 6.4, and made 27% with respect to saturated
ammonium sulfate. This sample was applied to a phenyl Sepharose gel (Pharmacia Fine Chem-
icals) in a 1.7 x 16-cm glass Econo Column (Bio-Rad Laboratories, Richmond, CA) at a
flow rate of 12 ml/h. After the sample had been applied, the column was rinsed with 27 0 10
ammonium sulfate in phosphate buffer until no more protein eluted from the column. Re-
maining column proteins were then eluted using a 300-ml linear gradient beginning with
27% ammonium sulfate, in 10 mM phosphate buffer, and ending with 50 0 1o ethylene glycol
in 4% ammonium sulfate, in phosphate buffer. After the completion ofthe gradient, the column
was stripped with 50% ethylene glycol in 10 mM phosphate buffer. The column fractions
containing maximum inhibitor activity were pooled, dialyzed, and concentrated using a YM-10
membrane.
HydroxylApatite Chromatography.
￿
The pooled material from the phenyl Sepharose column
was concentrated to a volume of 20-30 ml and diafiltered into 5 mM potassium phosphate
buffer, pH 6.8. This material was applied to a hydroxyl apatite gel (Bio-Rad Laboratories)
in a 1 x 18-cm glass Econo Column at a flow rate of 12 ml/h. After the sample was applied,
the column was washed with starting buffer until no more protein eluted. The remaining
bound proteins were then eluted with 0.4 M potassium phosphate buffer, pH 6.8. The pro-
teins that did not stick to the hydroxyl apatite column (5 mM phosphate buffer eluate) were
pooled for further processing.
Phenyl Superose Chromatography.
￿
The pooled material from the hydroxyl apatite column con-
taining IL-1 inhibitor was next subjected to hydrophobic affinity chromatography with a phenyl
Superose gel using a Fast Protein Liquid Chromatographic (FPLC)' apparatus (Pharmacia
Fine Chemicals). Pooled material was concentrated to a volume below 10 ml and diafiltered
into column running buffer (potassium phosphate buffer, pH 6 .4). This was brought to a
concentration of 27% saturated ammonium sulfate in phosphate buffer and applied to the
phenyl Superose column at a flow rate of 0.5 ml/min. The column was washed with 27%
saturated ammonium sulfate, and the retained proteins were then eluted using a 30-ml linear
gradient beginning with 27% saturated ammonium sulfate and ending with 10 mM potas-
sium phosphate buffer, pH 6.4. The fractions containing the maximum IL-1 inhibitor ac-
tivity were pooled and concentrated.
HPLC.
￿
The next step ofpurification was performed by hydrophobic interaction chroma-
tography (HIC-HPLC) using a high performance liquid chromatographic apparatus, (HP
1090, Hewlett-Packard Co., Palo Alto, CA), equipped with a 4.6 x 200-mm Poly Propyl Aspar-
tamide column (The Nest Group, Southborough, MA). Pooled material from the phenyl
Superose Column (20-30 gg) was concentrated on a Centricon 10 (Amicon Corp.) mem-
brane apparatus to a volume of 120 pl or less and diluted to 250 41 with 2 M ammonium
sulfate in 100 mM potassium phosphate, pH 6.0, without polyethylene glycol 1,000 (PEG-
1,000). The entire sample was injected on the column and eluted at a flow rate of 1.0 ml/min
on a 30-min linear gradient from 2.0 M ammonium sulfate in 100 mM potassium phosphate,
Abbreviations used in this paper: FPLC, fast protein liquid chromatography; PEG, polyethylene glycol;
HIC, hydrophobic interaction chromatography; PTH, phenylthiohydantoin.1770
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pH 6.0, to 100mM potassium phosphate, pH 6.0 . Fractions of0.5 ml were collected in tubes
containing 0.05 ml of PEG-1,000 (0.01 mg/ml) .
R versedphaseHPLC .
￿
HIC-HPLC-purified material was purified to homogeneity for amino
acid sequencing by reversed-phase HPLC . The chromatograph (HP 1090) was equipped with
a 4.6 mm x 2 cm-column packed with 5 gM, 300A Vydac C18 (The Separations Group,
Hisperia, CA) . Approximately 60 Rg of material purified by HIC-HPLC (Fig . 5, peak IV)
was concentrated to a volume of 500 p1 on a Centriprep 10 (Amicon Corp.) membrane ap-
paratus. The sample (250 ul) was injected and eluted at 1.5 ml/min on a linear solvent gra-
dient from 0.1% trifluoroacetic acid in water to 0.1% trifluoroacetic acid in 75% acetonitrile.
Fractions of 0.5 ml each were collected across the peak which eluted at 10.3 min (Fig . 6).
Fractions containing a single band with an M, of 38 kD by SDS-PAGE were subjected to
NH2-terminal amino acid sequencing .
Mouse Thymocyte Bioassay.
IL-1 inhibitor activity was measured using a mouse thymocyte bioassay (3) . 1-ml aliquots
of test samples were prepared for bioassay by dialysis in standard dialysis tubing that had
been boiled in double-distilled water with several changes . They were dialyzed at4°C against
-4 liters of 5 mM Hepes buffer, pH 7.5, with two changes over an 18-h period . Samples
were then made isotonic with 10 x RPMI, reconstituted with 1% heat-inactivated FCS, and
then sterilized by 0.22-gym micropore filtration (Millipore Continental Water Systems) . Samples
were tested at multiple dilutions depending on their estimated IL-1 inhibitory activity . They
were added to a single cell suspension ofmouse thymocytes to whichPHA (1 gg/ml) (purified
PHA; Burroughs Wellcome Co., Research Triangle Park, NY) and human rIL-la (2 U/ml,
Hoffman-La Roche Inc ., Nutley, NJ) had been added . Thymocytes were cultured for 72 h,
and IL-1 inhibitory activity was measured as previously described (3).
IL-1 inhibitory activity as measured in units/milliliter was calculated as the reciprocal of
the last dilution of sample that produced at least 30% inhibition .
SDS-PAGE Analysis and Protein Determinations .
Samples were analyzed for purity using SDS-PAGE analysis, as previously described (17) .
Aliquots (0 .1 ml) ofdialyzed samples were lyophilized, reconstituted with sample buffer con-
taining2-ME, boiled for 5 min, and 25-gl aliquots were subjected to electrophoresis on ei-
ther 10% SDS-polyacrylamide gels, or 10-20% gradient gels . Gels were stained with silver
nitrate. Protein concentrations were measured using a bicinchoninic acid protein assay (Pierce
Chemical Co ., Rockford, IL) .
Enzymatic Cleavage by Trylbsin.
Protein peaks from reversed-phase HPLC were dried in a Speed Vac Concentrator (Sa-
vant, Farmingdale, NY) . The dried residue was dissolved in 1% ammonium bicarbonate to
yield a solution of-0.5 mg/ml . Trypsin (TPCK treated; Serva Fine Biochemicals Inc., Garden
City Park, NY ; 1 mg/ml solution in water) was added (2% wt/wt from the protein sample
weight) and the mixture was incubated at 37°C. After 6 h a second portion of 2% wt/wt
trypsin was added and the incubation was continued overnight . The resulting tryptic pep-
tides were separated by reversed-phase HPLC using a C 18 column (ttBondapak; Waters As-
sociates, Milford, MA) (10-um particle diameter, 3.8 x 300 mm) . The mobile phases were
0 .1% trifluoroacetic acid in water (buffer A) and in acetonitrile (buffer B) . The gradient was
run from 0% to 55o7o B within 55min . Flow rate was 1 ml/min. Detection was done byUV
absorption at 214 and 280 nm, simultaneously . Two of the tryptic peptides were collected
manually, dried in a Speed Vac Concentrator, and used for sequencing .
Amino Acid Sequence Analysis .
The dried residue of protein or peptide peaks was dissolved in 75 Al 70% formic acid .
This solution was applied in three portions to the cartridge of a gas phase sequenator (model
470 A, Applied Biosystems, Inc ., Foster City, CA) . Sequencing was done by the program
39APTH, a slightly modified version of the program 02RPTH, which is supplied by the
manufacturer . The cleaved phenylthiohydantoin (PTH) amino acids were collected in a frac-ROSENSTREICH ET AL.
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tion collector, dried in a Speed Vac Concentrator, and redissolved in 50 ul ofthe mobile phase
of the HPLC system used for the identification . The HPLC system consisted of a Super-
sphere RPS column (Merck & Co ., Inc ., Rahway, NJ) (4-gm particle diameter, 4.6 x 250
mm) and an isocratic mobile phase of sodium acetate, acetonitrile, and dichloroethane (22) .
The flow rate was 1 ml/min . Detection was done by UV absorption at 254 nm . Retention
times ofPTH amino acids in the sequencer samples were compared with amino acid stan-
dards (Pierce Chemical Co.) .
Assayfor Deoxyribonuclease Activity.
The inhibitor(HPLC purified) was compared with bovine DNAase I (D-4513 ; SigmaChem-
ical Co.) for the ability to hydrolyze [' 4C]DNA (CFB . 170 ; Amersham Corp., Arlington
Heights, IL; sp act, 39 gCi/mg) . ['4C]DNA (0.2 gg) was incubated with 0.03 pg of bovine
DNAase I or the inhibitor in a 0.01 M Tris, 4mM MgC12 buffer, pH 7.0, in a total volume
of 0 .1 ml . At 15, 30, 60, and 90 min, the DNA was precipitated at 4°C by 5% TCA, 0.5%
Na2H2P20 7 . After a 15-min incubation period, the precipitated DNA was harvested onto
glass-fiber filter paper using a Skatron cell harvester (Flow Laboratories, Rockville, MD) with
a 5% TCA, 0.5% Na2H2P20, wash, followed by a 70% ethanol wash . Filters were dried and
cpm was determined by 0 scintillation counting .
Results
Initial Purification .
￿
Purification wasbegun with a batch ofpooled urine collected
in 40% saturated ammonium sulfate . This material was filtered, and proteins in-
soluble in 40°Jo ammonium sulfate were discarded . The solution was then concen-
trated in a hollow fiber concentrator, diafiltered to remove ammonium sulfate, and
brought to a final concentration of ti1,000 ml . The soluble proteins were then precipi-
tated using 80% saturated ammonium sulfate, and resolubilized in water and dia-
lysed . At this stage, the volume of sample was -800 ml . This material was then ap-
plied to a large ion exchange column, and the proteins that eluted at sodium chloride
concentrations between 51 and 250mMwere collected and pooled . Previous studies
and preliminary results indicated that this initial purification method resulted in
the highest recovery of inhibitory activity (17) .
Chromatographic Purification.
￿
The material from the ion exchange column was next
subjected to molecular sieve chromatography on an ACA-54 gel . Proteins eluted
from thiscolumn with a small void volume peak, followed by a broad, asymmetrical
peak ranging in apparent molecular mass from 80 to -20 kD (Fig . 1) . IL-1 inhib-
itor activity was found to elute from this column in a symmetrical peak with an
FIGURE 1 .
￿
Molecular sieve chromatography. A
6-ml sample of the IL-1 inhibitor-rich pool from
the Tris-acrylDEAE step (50-250 mM cut) was
applied to the column containing ACA-54 geland
eluted with PBS at a flow rate of 28 ml/h . Frac-
tion size, 3 .8 ml.1772
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apparent molecularmass of-40kD. A smaller amount of inhibitory activity eluted
with the void volume peak . This material was processed separately.
Thepooled IL-1 inhibitorcontaining material from theACA-54 column was next
applied to a phenyl Sepharose column . The majority of the applied proteins ad-
hered to this column and began to elute when N40% of the gradient had gone
through the column (Fig . 2) . IL-1 inhibitory activity was found in a symmetrical
peak in the latter two thirds of the gradient run . IL-1 inhibitory activity began to
elute when the elution buffer contained 15% ammonium sulfate and25% ethylene
glycol and was substantiallyremoved from thecolumnwhen the elution buffer con-
tained 9% ammonium sulfate and 40% ethylene glycol .
IL-inhibitory material was pooled, concentrated, and subjected to hydroxylapa-
tite chromatography. Preliminary testing with both linear and stepwise gradients
indicated that 70-90°Jo ofthe IL-1 inhibitor activity did not adhere to hydroxylapa-
tite in 5mM phosphate buffer, and the remainder of the activity eluted in a very
broad peak ranging from 10 to 200mM phosphate buffer. Material was therefore
eluted from the column using a two-step gradient . The elution profile consisted of
a broad peak of proteins that did not stick to the column in 5mM phosphate buffer
(Fig . 3, fractions Iand II), followed by a very sharp peak as the rest of the proteins
were stripped from the column with 0.4 M phosphate buffer (Fig . 3, fraction IV) .
As indicated, -80% ofthe IL-1 inhibitory activity did not stick to this column, and
the remainder eluted with the high phosphate buffer.
The remainder of the purification was performed on the material that did not
stick to hydroxylapatite (Fig. 3, fractions I and II), since this was found to contain
higher specific activity and fewer contaminating proteins . Fractions I and II from
the hydroxyl apatite column were pooled, concentrated, and next subjected to hy-
drophobic affinity chromatography using an FPLC apparatus fitted with a phenyl
Superose column . The bulk of the proteins adhered to this column . The elution
profile consisted ofabroad shallow peak in the early phase of the gradient followed
by one to two sharp peaks that eluted close to the end of the gradient (Fig. 4) . IL-1
inhibitory activity was found to elute at ammonium sulfate concentrations ranging
between 10% and 15%, and corresponded to two small protein peaks that immedi-
ately preceded the last peak .
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FIGURE 2 .
￿
Hydrophobic chro-
matography . A 7-ml sample of
the IL-1 inhibitor pool from the
ACA-54 step(see Fig . 1) in 27%
ammonium sulfate was applied
to a column containing phenyl
Sepharose gel and eluted at a
flow rate of 12 ml/h as described
in Materials and Methods .
Fraction size, 3 ml.The material from the phenyl Superose was pooled, concentrated, and applied
to a polypropyl aspartamide column using an HPLC apparatus . This resulted in
a UV absorbance (210 nM) elution profile with an early peak, a broader middle
region containing three peaks, and a late, sharp peak (Fig . 5, I, III, and IV, respec-
tively) at the end of the gradient . IL-1 inhibitory activity was found to elute exclu-
sively in the last peak .
The inhibitor rich peak from the polypropyl aspartamide column was subjected
to a final purification by reversed-phase HPLC . When chromatographed on a C18
column, theinhibitor rich material eluted as asharp homogeneous peak with areten-
tion time of 10.3 min(Fig . 6) .A small, broad peak containing residual contaminating
proteins eluted immediately before the inhibitor (9.5 min) .
Purification of IL-1 Inhibitorfrorn a Single Batch of Urine.
￿
IL-1 inhibitor was next
purified from 70 liters of urine using the preceding eight-step sequence .
0
2.7
5.4
8.1
H 10.8
E
135
16.2
e
~9'a, 18.9
21.6
24.3
270
PHENYL SUPEROSE "FPLC "
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FIGURE 3 .
￿
Hydroxyl apatitechromatog-
raphy . A 4.5-ml sample ofthe IL-1 inhib-
itor pool from the phenyl Sepharose step
(see Fig . 2) in 5mM potassium phosphate
buffer wasapplied to acolumn containing
hydroxyl apatite gel and eluted at a flow
rate of 12 ml/h, as described in Materials
and Methods. Fraction size, 3 ml .
FIGURE 4 .
￿
Fast protein liquid chromatography . A
1.5-ml sample of the IL-1 inhibitor pool from the
hydroxyl apatite column (see Fig. 3) in 27% ammo-
nium sulfate, was applied to a phenyl Superose
column usinga fast protein liquid chromatographic
apparatusand eluted as described in Materialsand
Methods. Fraction size, 1 ml .1774
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IL-1 inhibitor-containing samples from each of the chromatographic steps were
subjected to SDS-PAGE, and gels were stained with silver. As expected, early frac-
tions were contaminated with multiple proteins (Fig . 7) . However, purification of
IL-1 inhibitor activity was associated with increasing concentrations ofa38-kD band .
The inhibitor preparation that resulted from the HPLC step (propyl aspartamide)
was essentiallyhomogeneous . Bands that appear at 55 and 68kD (Fig . 7, lanes 3-5)
represent skin keratins that occasionally contaminate SDS-PAGE buffer solutions
(23) . The preparation resulting from the second HPLC step (reversed phase) also
contained only the 38-kD band.
To be certain that the 38-kD protein was the thymocyte inhibitor, material from
another purification run (through the propyl aspartamide step) wassubjectedto SDS-
PAGE analysis (Fig. 7, lane 7) . This preparation also contained the 38-kD band,
but the higher molecular mass contaminants were not present.
Purification of the inhibitor resulted in a significant increase in specific activity.
Pooled material from the ACA-54columnhad a sp act of 581 U/mg whilethe homo-
geneous propyl aspartamide purified pool had a sp act of 3.4 x 104 U/mg (Fig . 7) .
The material from the reverse-phase column was not tested for biological activity
since the elutionconditions destroy inhibitor activity. The propyl aspartamide-purified
material from the second run also had a high sp act (9 x 104 U/mg). Overall yield
of biologically active inhibitor after the propyl aspartamide step was -1%.
AminoAcid Sequence.
￿
A partial amino acid sequence of thereversed-phase HPLC-
purified inhibitorpreparationwasdetermined . Information was obtained on the first
23 NH2-terminal amino acids, as well as on two peptide fragments representing
amino acids 48-60 and 61-70(Fig . 8) . Comparison ofthe unambiguous amino acid
0.06
00.04
a
0.02H
Reversed Phase
FIGURE 5 .
￿
Hydrophic interaction chro-
matography . A 0.5-ml (25 ug) sample of
the IL-1 inhibitor pool from the phenyl Su-
perose column (see Fig. 4) in 2Mammo-
nium sulfate was applied to a polypropyl
aspartamide column usinganHPLC ap-
paratus, and eluted at a flow rate of 1
ml/min as described in Materials and
Methods . Fraction size, 0.5 ml.
FIGURE 6.
￿
Reversed-phase chromatography. A0.25-
ml (30 jig) sample of HIC-HPLC-purified inhibitor
(see Fig. 5) was injected on a4.6mm x 20mm Vydac
C18 column and eluted at 1.5 ml/min as described
in Materials and Methods . Fraction size, 1.5 ml .ROSENSTREICH ET AL .
￿
1775
FIGURE 7 . SDS-PAGE anal-
ysis . Samples of the inhibitor
pools from each of the chro-
matographic steps were diluted
1:10, dialyzedto remove all salts,
and lyophilized . Samples were
reconstituted with 50 Al of
sample buffer containing2-ME
and boiled for5 min . 25 ul ali-
quots were then subjected to
electrophoresis on a 10% SDS-
polyacrylamide gel, fixed,
washed, and stained with silver
nitrate. Lane 1, ACA-54 ; lane
2, phenyl Sepharose ; lane 3,
hydroxyl apatite; lane 4, phenyl
Superose ; lane 5, propyl aspar-
tamide ; lane 6, reversed-phase
HPLC ; lane 7, propylasparta-
mide-purified material from a
second purification run (10-
20% gradient gel).
sequence with the European Molecular Biology Laboratory (Heidelberg, Federal
Republic ofGermany) protein data bank revealed that this portion of the inhibitor
had at least a 78% homology with bovine DNase I . No human DNase sequence
was available for comparison .
DNase Activity of the Inhibitor.
￿
Because of the sequence homology with DNase I,
the purified inhibitorpreparation (propyl aspartamidepool)was analyzed forDNase
activity in vitro. LabeledDNA was incubated with equivalent concentrations of ei-
ther the inhibitor, or a sample of bovine DNase I . After 15, 30, 60, and 90 min,
DNA hydrolysis was measured by determining residual TCA-precipitable counts .
The inhibitor was found to degradeDNA as actively as the authentic enzyme (Fig.
9) . These data, in conjunctionwith the amino acid sequence findings, strongly sug-
gest that the human urine-derived inhibitor is a type of DNase 1 .
Discussion
The human urine-derived febrile inhibitor has been purified to apparent
homogeneity using a sequence of eight purification steps . Upon SDS-PAGE anal-
ysis (reduced) using a sensitive silver stain, this protein appears to be 38 kD in size,
and the final material appears to be devoid ofany other detectable protein impuri-
ties . The purified material is active in vitro in the nanogram range, with a sp act
of 34,666 IL-1 inhibitorU/mg. Partial amino acid sequence analysis ofthe purified
inhibitor suggests a close homology with other mammalian (bovine, porcine, and
ovine) DNase I enzymes (24) . Furthermore, the inhibitorwas found to have as po-
tent enzymatic activity as a bovine pancreatic DNase I standard . Finally, prelimi-
nary experimentsin our laboratory demonstratethat concentrations of bovine pan-
creatic DNase I preparations exhibit thymocyte inhibitory activity. These findings
strongly suggest that the inhibitor of IL-1-induced thymocyte proliferation found
in the urine of febrile individuals is a type of DNase I .1776
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FIGURE 8 .
￿
Partialamino acid sequence of the human urine-derived IL-L inhibitor. (?) Could
not be identified unambiguously . (X)A cycle where no amino acid could be found .
Available evidence also indicates that the inhibitor is ofhuman origin . Recent
experiments in our laboratory revealed that it contains alarge amount ofN-linked
sugars, indicating that it is not derived from bacteria (data not shown) . Some viral
glycoproteins have been found to inhibit IL-1 (25, 26) . However, the closehomology
between the inhibitor and other mammalianDNase enzymes argues against a viral
origin. Otherrecent experimentsin ourlaboratory indicate that a monospecific rabbit
anti-inhibitor antibody does not crossreact with any bovine DNasepreparation (data
not shown) . This fact, in conjunction with the differences between the amino acid
sequence of the inhibitor and other mammalian DNase I enzymes already found,
make it likely that the inhibitor is ahuman DNase I.
DNase I-like enzymes have been identified in numerous organs of the rat, in-
cluding large amounts in lymph node and kidney, and smaller amounts in blood
cells (27) . Interestingly, most of these tissues contain a 31-kD DNase I, except for
kidney, which contains an additional higher molecular mass enzyme of -36 kD.
Although asimilar high molecular massDNase hasnotyet been reported inhumans,
it is likely that thehuman urine-derived IL-1 inhibitor is related to the higher mo-
lecular mass form of the rat kidney DNase I.
Several otherIL-1 inhibitors have been isolated from human urine . Based on this
FIGURE 9 .
￿
DNAase activity ofthe inhibitor.
Samples of DNAase I and the purified inhib-
itor were incubated with 0.2 ug of ['4C]DNA .
DNA hydrolysis was determined by the loss
of TCA precipitable counts .
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purification as well as previous findings, the febrile inhibitor appears to be distinct
from each of these. Ourearlierdata strongly suggestedthat it wasdistinct from uro-
modulin, the 85-kD molecule that is present in large amounts in the urine of preg-
nant women (2). The evidence included differences in size and a lack of antigenic
crossreactivity (19). We had also noted that the febrile inhibitor exerted its effect
late in the activation cycle of thymocytes (19), whereas uromodulin, which appears
to act by binding IL-1, only inhibits when added relatively early during thymocyte
culture (28). Since there is aclose connection between uromodulin and the Tamm-
Horsfall glycoprotein (28, 29), the finding in this paper confirming the lowermolec-
ular weight of the febrile inhibitor further supports the suggestion that the febrile
inhibitor and uromodulin are distinct molecules.
The febrile inhibitor is also distinguishable from the inhibitor first found in the
urine of a patient with monocytic leukemia by Dayer and coworkers (5, 21), since
thelatter molecule is smallerin size (20-25 kD) than thefebrile inhibitor. The mono-
cytic inhibitor also appears to block IL-1-induced fibroblast PGE2 production, while
no preparation of febrile inhibitor has ever blocked fibroblast activity (30). Dayer
and MacDonald (21) have also reported that this lower molecular weight inhibitor
blocks the bindingofIL-1 to its receptor whilethe febrile inhibitordoes not interfere
with IL-1-R binding when tested either indirectly (19) or directly (D. Rosenstreich,
manuscript in preparation).
On the otherhand, over the past 10 yr, there have been numerous reports of IL-1
inhibitors derived from various sources that block thymocyte proliferation in vitro
(6-16). It is possible that some or all of these may be DNase-like molecules, and
the findings presented in this report may help to clarify or reconcile some of these
disparate observations. This hypothesis is amenable to experimental verification using
established methodology.
There remain a number of interesting and important questions about the IL-1
inhibitor, including its mechanism of action in vitro, its cellular source and tissue
of origin, and its physiologic role. Answering many of these questions should be
facilitated by its recent purification and identification.
Summary
We have previously reported that theurineof febrile humans containedlarge quan-
tities of an inhibitorof IL-1-induced murine thymocyteproliferation that was a gly-
coprotein between 30 and 40 kD in size. In the present study this factor has been
purified to homogeneity using a sequence of eight purification steps (ammonium
sulfate precipitation, ion exchange chromatography, molecular sieve chromatography,
hydrophobic affinity chromatography, hydroxylapatite chromatography, fast protein
liquid chromatography, and two HPLC steps) . SDS-PAGE analysis indicates that
the purified material is a 38-kD molecule. Evidence based on a partial amino acid
sequence analysis as well as enzyme studies indicates that this inhibitor is a type
of human DNase I.
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